WO2001047879A1 - Pyrrolidines which inhibit camp-specific pde - Google Patents
Pyrrolidines which inhibit camp-specific pde Download PDFInfo
- Publication number
- WO2001047879A1 WO2001047879A1 PCT/US2000/034116 US0034116W WO0147879A1 WO 2001047879 A1 WO2001047879 A1 WO 2001047879A1 US 0034116 W US0034116 W US 0034116W WO 0147879 A1 WO0147879 A1 WO 0147879A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- compound
- methoxyphenyl
- cyclopentyloxy
- hydrogen
- Prior art date
Links
- 0 CN(*)C(*)(*)C(*)(CN(*)C1)C1(**)c(cc1)cc(O*)c1O* Chemical compound CN(*)C(*)(*)C(*)(CN(*)C1)C1(**)c(cc1)cc(O*)c1O* 0.000 description 12
- AJDCOTRGZXUEMA-UHFFFAOYSA-N CC1C2C1CCC2 Chemical compound CC1C2C1CCC2 AJDCOTRGZXUEMA-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a series of compounds that are potent and selective inhibitors of cyclic adenosine 3 ' , 5 ' -monophosphate specific phosphodiesterase (cAMP specific PDE) .
- cAMP specific PDE cyclic adenosine 3 ' , 5 ' -monophosphate specific phosphodiesterase
- the present invention relates to a series of novel compounds that are useful for inhibiting the function of cAMP specific PDE, in particular, PDE4 , as well as methods of making the same, pharmaceutical compositions containing the same, and their use as therapeutic agents, for example, in treating inflammatory diseases and other diseases involving elevated levels of cytokines and proin- flammatory mediators .
- Chronic inflammation is a multi-factorial disease complication characterized by activation of multiple types of inflammatory cells, particularly cells of lymphoid lineage (including T lymphocytes) and myeloid lineage (including granulocytes, macro- phages, and monocytes) .
- Proinflammatory mediators including cytokines, such as tumor necrosis factor (TNF) and interleukin-1 (IL-1) , are produced by these activated cells. Accordingly, an agent that suppresses the activation of these cells, or their production of proinflammatory cytokines, would be useful in the therapeutic treatment of inflammatory diseases and other diseases involving elevated levels of cytokines.
- Cyclic adenosine monophosphate is a second messenger that mediates the biologic re- sponses of cells to a wide range of extracellular stimuli.
- adenylate cyclase is activated to convert adenosine triphosphate (ATP) to cAMP .
- ATP adenosine triphosphate
- cAMP intracellular actions terminated by either a transport of the nucleotide to the outside of the cell, or by enzymatic cleavage by cyclic nucleotide phosphodiesterases (PDEs) , which hydrolyze the 3 ' -phosphodiester bond to form 5' -adenosine monophosphate (5 '-AMP) .
- PDEs cyclic nucleotide phosphodiesterases
- Elevated levels of cAMP in human myeloid and lymphoid lineage cells are associated with the suppression of cell activation.
- the intracellular enzyme family of PDEs therefore, regulates the level of cAMP in cells.
- PDE4 is a predominant PDE isotype in these cells, and is a major contributor to cAMP degradation. Accordingly, the inhibition of PDE function would prevent the conversion of cAMP to the inactive metabolite 5 ' -AMP and, consequently, maintain higher cAMP levels, and, accordingly, suppress cell activation (see Beavo et al . , "Cyclic Nucleotide Phosphodiesterases : Structure, Regulation and Drug Action," Wiley and Sons, Chichester, pp.
- PDE4 inhibitors such as rolipram
- PDE4 inhibitors have been shown to inhibit production of TNF ⁇ and partially inhibit IL-1? release by ono- cytes (see Semmler et al . , Int . J. Immunophar acol . , 15, pp. 409-413 (1993); Molnar-Kimber et al . , Media- tors of Inflamma tion, 1 , pp.
- PDE4 inhibitors also have been shown to inhibit the production of superoxide radicals from human poly- morphonuclear leukocytes (see Verghese et al . , J. Mol . Cell . Cardiol . , 21 (Suppl . 2) , S61 (1989); Nielson et al . , J “ . Allergy Immunol . , 86, pp. 801-808 (1990) ) ; to inhibit the release of vasoactive amines and prostanoids from human basophils (see Peachell et al . , J. Immunol . , 148 , pp.
- Inflammatory cell activation and excessive or unregulated cytokine (e.g., TNF ⁇ and IL-13) production are implicated in allergic, autoimmune, and inflammatory diseases and disorders, such as rheuma- toid arthritis, osteoarthritis , gouty arthritis, spondylitis, thyroid associated ophthalmopathy, Behcet ' s disease, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, toxic shock syndrome, asthma, chronic bronchitis, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, such as chronic obstructive pulmonary disease, silicosis, pulmonary sarco- idosis, reperfusion injury of the myocardium, brain, and extremities, fibrosis, cystic fibrosis, keloid formation, scar formation, atherosclerosis, transplant rejection disorders, such as graft vs.
- diseases and disorders such as rheuma- toid arthritis, osteoarth
- inflammatory bowel disease such as Crohn's disease and ulcerative colitis
- prolif- erative lymphocyte diseases such as leukemia
- inflammatory dermatoses such as atopic dermatitis, psoriasis, and urticaria.
- cytokine levels include brain injury due to moderate trauma (see Dhillon et al . , J “ . Neurotrauma , 12, pp. 1035-1043 (1995); Suttorp. et al . , J “ . Clin . Invest . , 91 , pp. 1421-1428 (1993)), cardiomyopathies , such as congestive heart failure (see Bristow et al . , Circu- lation, 97, pp.
- cachexia cachexia secondary to infection or malignancy
- cachexia secondary to acquired immune deficiency syndrome AIDS
- ARC AIDS related complex
- fever myalgias due to infection cerebral malaria, osteoporosis and bone resorption diseases, keloid formation, scar tissue formation, and pyrexia.
- TNF ⁇ has been identified as having a role with respect to human acquired immune deficiency syndrome (AIDS) .
- AIDS results from the infection of T-lymphocytes with Human Immunodeficiency Virus (HIV) .
- HIV Human Immunodeficiency Virus
- TNF has been shown to upregulate HIV infection in T-lymphocytic and monocytic cells (see Poli et al . , Proc. Natl . Acad. Sci . USA, 87, pp. 782-785 (1990)).
- TNF ⁇ Several properties of TNF ⁇ , such as stimulation of collagenases, stimulation of angiogenesis in vivo, stimulation of bone resorption, and an ability to increase the adherence of tumor cells to endothelium, are consistent with a role for TNF in the development and metastatic spread of cancer in the host. TNF ⁇ recently has been directly impli- cated in the promotion of growth and metastasis of tumor cells • (see Orosz et al . , J: Exp . Med. , 177, pp. 1391-1398 (1993) ) .
- PDE4 has a wide tissue distribution. There are at least four genes for PDE4 of which multiple transcripts from any given gene can yield several different proteins that share identical catalytic sites. The amino acid identity between the four possible catalytic sites is greater than 85%. Their shared sensitivity to inhibitors and their kinetic similarity reflect the functional aspect of this level of amino acid identity. It is theorized that the role of these alternatively expressed PDE4 proteins allows a mechanism by which a cell can differentially localize these enzymes intracellularly and/or regulate the catalytic efficiency via post translational modification. Any given cell type that expresses the PDE4 enzyme typi- cally expresses more than one of the four possible genes encoding these proteins .
- PDE4 inhibitors have shown considerable interest in the use of PDE4 inhibitors as anti-in- flammatory agents. Early evidence indicates that PDE4 inhibition has beneficial effects on a variety of inflammatory cells such as monocytes, macro- phages, T-cells of the Th-1 lineage, and granulo- cytes . The synthesis and/or release of: many proinflammatory mediators, such as cytokines, lipid mediators, superoxide, and biogenic amines, such as histamine, have been attenuated in these cells by the action of PDE4 inhibitors.
- proinflammatory mediators such as cytokines, lipid mediators, superoxide, and biogenic amines, such as histamine
- the PDE4 inhibitors also affect other cellular functions including T- cell proliferation, granulocyte transmigration in response to chemotoxic substances, and integrity of endothelial cell junctions within the vasculature.
- Methyl - xanthines such as caffeine and theophylline, were the first PDE inhibitors discovered, but these compounds are nonselective with respect to which PDE is inhibited.
- the drug rolipram an antidepressant agent, was one of the first reported specific PDE4 inhibitors.
- Rolipram having the following structural formula, has a reported 50% Inhibitory Concentration (IC 50 ) of about 200 nM (nanomolar) with respect to inhibiting recombinant human PDE4.
- PDE4 inhibitors that are more selective with respect to inhibiting PDE4 , that have a lower IC 50 than rolipram, and that avoid the undesirable central nervous system (CNS) side effects, such as retching, vomiting, and sedation, associated with the administration of rolipram.
- CNS central nervous system
- One class of compounds is disclosed in Feldman et al . U.S. Patent No. 5,665,754.
- the compounds disclosed therein are substituted pyrrolidines having a structure similar to rolipram.
- One particular compound, having structural formula (I) has an IC 50 with respect to human recombinant PDE4 of about 2 nM. Inasmuch as a favorable separation of emetic side effect from efficacy was observed, these compounds did not exhibit a reduction in undesirable CNS effects.
- PDE4 inhibitors In addition, several companies are now undertaking clinical trials of other PDE4 inhibitors. However, problems relating to efficacy and adverse side effects, such as emesis and central nervous system disturbances, remain unsolved. Accordingly, compounds that selectively inhibit PDE4 , and that reduce or eliminate the adverse CNS side effects associated with prior PDE4 inhibitors, would be useful in the treatment of allergic and inflammatory diseases, and other dis- eases associated with excessive or unregulated production of cytokines, such as TNF. In addition, selective PDE4 inhibitors would be useful in the treatment of diseases that are associated with elevated cAMP levels or PDE4 function in a particular target tissue.
- the present invention is directed to po- tent and selective PDE4 inhibitors useful in treatment of diseases and conditions where inhibition of PDE4 activity is considered beneficial.
- the present PDE4 inhibitors unexpectedly reduce or eliminate the adverse CNS side effects associated with prior PDE4 inhibitors .
- the present invention is directed to compounds having the structural formula (ID :
- R 1 is lower alkyl , bridged alkyl (e.g., norbornyl) , aryl , heteroaryl, aralkyl, cyclo- alkyl (e.g., indanyl) , a 5- or 6-membered saturated heterocycle (e.g., 3-tetrahydrofuryl) , C ⁇ alkylene- aryl , C- ⁇ alkyleneOaryl , C 1 . 4 alkyleneheteroaryl , C 1 _ 4 alkyleneHet , C 2 _ 4 alkylenearylOaryl , C 1 .
- C ⁇ alkylenecycloalkyl e.g., cyclo- pentylmethyl
- substituted or unsubstituted propargyl e.g., -CH 2 C ⁇ C-C 6 H 5
- halocyclo- alkyl e.g., fluorocyclopenty
- R 2 is hydrogen, methyl, or halo-substituted methyl, e.g., CHF 2 ;
- R 4 is hydrogen, lower alkyl, haloalkyl, cycloalkyl, or aryl ;
- R 5 is hydrogen, lower alkyl, alkynyl, haloalkyl, cycloalkyl, or aryl;
- R 7 is selected from the group consisting of branched or unbranched lower alkyl, heteroaryl, a heterocycle, aralkyl, and.
- aryl, and R 7 can be optionally substituted with one or more of OR 8 , NR 8 R 9 , or SR 8 ;
- R 8 and R 9 same or different; are selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, alkaryl , heteroaralkyl, heteroalkaryl, and aralkyl, or R 8 and R 9 can be taken together form a 4 -membered to 7 -membered ring;
- the present invention also is directed to pharmaceutical compositions containing one or more of the compounds of structural formula (II) , to use of the compounds and compositions containing the compounds in the treatment of a disease or disorder, and to methods of preparing compounds and intermediates involved in the synthesis of the compounds of structural formula (II) .
- the present invention also is directed to methods of treating a mammal having a condition where inhibition of PDE4 provides a benefit, modulating cAMP levels in a mammal, reducing TNF ⁇ levels in a mammal, suppressing inflammatory cell activation in a mammal, and inhibiting.
- PDE4 function in a mammal by administering therapeutically effective amounts of a compound of structural formula (II) , or a composition containing a composition of structural formula (II) to the mammal.
- the present invention is directed to compounds having the structural formula (II) :
- R 1 is lower alkyl, bridged alkyl (e.g., norbornyl) , aryl, heteroaryl, aralkyl, cycloalkyl (e.g., indanyl), a 5- or 6-membered saturated heterocycle (e.g., 3 -tetrahydrofuryl) , C ⁇ alkylene- aryl , C 1 . 4 alkyleneOaryl , C r .. 4 alkyleneheteroaryl , bridged alkyl, C 1 .
- alkylenecycloalkyl e.g., cyclo- pentylmethyl
- substituted or unsubstituted propargyl i.e., -CH 2 C ⁇ C-C 6 H 5
- halocyclo- alkyl e.g., fluorocyclopentyl
- R 2 is hydrogen, methyl, or halo-substituted methyl , e.g., CHF 2 ;
- R 3 is selected from the group consisting of
- R 4 is hydrogen, lower alkyl, haloalkyl, cycloalkyl, or aryl;
- R 5 is hydrogen, lower alkyl, alkynyl, haloalkyl, cycloalkyl, or aryl;
- R 7 is selected from the group consisting of branched or unbranched lower alkyl, heteroaryl, a heterocycle, aralkyl, and aryl, and R 7 can be optionally substituted with one or more of OR 8 , NR 8 R 9 , or SR 8 ;
- R 8 and R 9 same or different, are selected from the group consisting of hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, alkaryl, heteroar- alkyl, heteroalkaryl, and -aralkyl, or R 8 and R 9 can be taken together form a 4 -membered to 7-membered ring;
- R 11 is alkyl, cycloalkyl, trifluoromethyl, aryl, aralkyl, or NR 8 R 9 ; and salts and solvates (e.g., hydrates) thereof .
- alkyl is defined to include straight chain and branched chain saturated hydrocarbon groups containing one to 16 carbon atoms.
- the term “lower alkyl” is defined herein as an alkyl group having one through six carbon atoms (Ci-Cg) . Examples of lower alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, isobutyl, n- butyl , neopentyl, n-hexyl, and the like.
- alkynyl refers to an unsaturated alkyl group that contains a carbon-carbon triple bond.
- bridged alkyl is defined herein as a C 6 -C 16 bicyclic or polycyclic hydrocarbon group, for example, norboryl , adamantyl , bicyclo [2.2.2] - octyl, bicyclo [2.2.1] heptyl, bicyclo [3.2.1] octyl , or decahydronaphthyl .
- cycloalkyl is defined herein to include cyclic C 3 -C 7 hydrocarbon groups, optionally fused to an aromatic group.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl , cyclohexyl , cyclopentyl , indanyl , and tetrahydronaphthyl .
- alkylene refers to an alkyl group having a substituent .
- C 1 . 3 alkylenecycloalkyl refers to an alkyl group containing one to three carbon atoms, and substituted with a cycloalkyl group.
- haloalkyl is defined herein as an alkyl group substituted with one or more halo substituents, either fluro, chloro, bromo, iodo, or combinations thereof.
- halocycloalkyl is defined as a cycloalkyl group having one or more halo substituents.
- aryl alone or in combination, is defined herein as a monocyclic or polycyclic aromatic group, preferably a monocyclic or bicyclic aromatic group, e.g., phenyl or naphthyl, that can be unsubstituted or substituted, for example, with one or more, and in particular one to three, substituents selected from halo, alkyl, phenyl , hydroxy, hydroxyalkyl , alkoxy, alkoxyalkyl , haloalkyl, nitro, amino, alkylamino, acylamino, alkyl - thio, alkylsulfinyl , and alkylsulfonyl .
- Exemplary aryl groups include phenyl, naphthyl , tetrahydro- naphthyl, 2-chlorophenyl , 3-chlorophenyl , 4-chloro- phenyl , 2 -methylphenyl , 4-methoxyphenyl , 3 -tri - fluoromethyl-phenyl , 4-nitrophenyl , and the like.
- heteroaryl is defined herein as a monocyclic or bicyclic ring system containing one or two aromatic rings and containing at least one nitrogen, oxygen, or sulfur atom in an aromatic ring, and which can be unsubstituted or - substituted, for example, with one or more, and in particular one to three, substituents, like halo, alkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkyl, nitro, amino, alkylamino, acylamino, alkylthio, alkylsulfinyl, and alkylsulfonyl . Examples of heteroaryl .
- groups include thienyl, furyl , pyridyl, oxazolyl, quinolyl , isoquinolyl, indolyl, triazolyl, isothi- azolyl , isoxazolyl, imidizolyl, benzothiazolyl , pyrazinyl, pyrimidinyl , thiazolyl, and thiadiazolyl .
- aralkyl is defined herein as a previously defined alkyl group, wherein one of the hydrogen atoms is replaced by an aryl group as defined herein, for example, a phenyl group optionally having one or more substituents, for example, halo, alkyl, alkoxy, and the like.
- An example of an aralkyl group is a benzyl group.
- alkaryl is defined herein as a previously defined aryl group, wherein one of the hydrogen atoms is replaced by an alkyl, cycloalkyl, haloalkyl, or halocycloalkyl group.
- heteroarylkyl and “heteroalkaryl” are defined similarly as the term “aralkyl” and “alkaryl,” however, the aryl group is replaced by a heteroaryl group as previously defined.
- heterocycle is defined as a 5- or 6-membered_ nonaro atic ring having one or more heteroatoms selected from oxygen, nitrogen, and ' sulfur present in the ring.
- Nonlimiting examples include tetrahydrofuran, piperidine, piperazine, sulfolane, morpholine, tetrahydropyran, dioxane, and the like.
- halogen or "halo" is defined ⁇ ⁇ herein to include fluorine, chlorine, bromine, and iodine .
- alkoxy is defined as -OR, wherein R is alkyl, aryl, and aralkyl, respectively.
- alkoxyalkyl is defined as an alkoxy group appended to an alkyl group .
- aryloxyalkyl and “aralkoxyalkyl” are similarly defined as an aryloxy or aralkoxy group appended to an alkyl group.
- hydroxy is defined as -OH.
- hydroxyalkyl is defined as a hydroxy group appended to an alkyl group .
- amino is defined as -NH 2 .
- alkylamino is defined as -NR 2 wherein at least one R is alkyl and the second R is alkyl or hydrogen.
- nitro is defined as -N0 2 .
- alkylthio is defined as -SR, where R is alkyl .
- alkylsulfinyl is defined as R-S0 2 , where R is alkyl.
- alkylsulfonyl is defined as R-S0 3 , where R is alkyl.
- R 5 is hydrogen or methyl
- R 7 is methyl
- R 2 is methyl or difluoromethyl
- R 4 is selected from the group consisting of hydrogen, lower alkyl, benzyl, and phenyl
- R 12 is hydrogen or methyl
- R 1 is selected from the group consisting of
- R 1 is selected from the group consisting of cyclopentyl, cyclopropylmethyl , tetrahydrofuryl, indanyl, norbornyl , phenethyl , and phenylbutyl ;
- R 2 is selected from the group consisting of methyl and difluoro- methyl;
- the present invention includes all possi- ble stereoisomers and geometric isomers of compounds of structural formula (II) , and includes not only racemic compounds but also the optically active isomers as well.
- a compound of structural formula (II) is desired as a single enantiomer, it can be obtained either by resolution of the final product or by stereospecific synthesis from either isomerically pure starting material or use of a chiral auxiliary reagent, for example, see Z. Ma et al . , Tetrahedron : Asymmetry, 8 (6) , pages 883-888 (1997) . Resolution of the final product, an intermediate, or a starting material can be achieved by any suitable method known in the art.
- the present invention is intended to include all tautomeric forms of the compounds.
- specific stereoisomers exhibit an exceptional abil- ity to inhibit PDE4 without manifesting the adverse CNS side effects typically associated with PDE4 inhibitors .
- rolipram is a stereospecific PDE4 inhibitor that" contains one chiral center.
- the ( -) -enantiomer of rolipram has a higher pharmacolog- ' ical potency than the (+) -enantiomer, which could be related to its potential antidepressant ' action.
- Schultz et al . Naunyn-S ⁇ hmiedeberg ' s Arch Pharmacol , 333:23-30 (1986).
- the metabolism of rolipram appears stereospecific with the (+) - enantiomer exhibiting a faster clearance rate than the (-) -enantiomer .
- Krause et al the metabolism of rolipram appears stereospecific with the (+) - enantiomer exhibiting a faster clearance rate than the (-) -enantiomer .
- (+) -enantiomer (S-rolipram) .
- S-rolipram (+) -enantiomer
- the compounds of the present invention can have three or more chiral centers. As shown below, compounds of a speci-fic stereochemical orientation exhibit similar PDE4 inhibitory activity and pharmacological activity, but altered CNS toxicity and emetic potential.
- preferred' compounds of the present invention have the structural formula (III) :
- the compounds of structural formula (III) are potent and selective PDE4 inhibitors, and do not manifest the adverse CNS effects and emetic potential demon- strated by stereoisomers of a compound of structural formula (III) .
- Compounds of structural formula (II) which contain acidic moieties can form pharmaceutically acceptable salts with suitable cations.
- suitable pharmaceutically acceptable cations include alkali metal (e.g., sodium or potassium.) and alkaline earth metal (e.g., calcium or magnesium) cations.
- the pharmaceutically acceptable salts of the compounds of structural formula (II) which contain a basic center, are acid addition salts formed with pharmaceutically acceptable acids.
- Examples include the hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, -citrate, tartrate, gluconate, methanesulfonate, benzene- sulphonate, and p-toluenesulphonate salts.
- any reference to compounds of the present invention appearing herein is intended to include compounds of structural formula (II) , as well as pharmaceutically acceptable salts and solvates thereof .
- the compounds of the present invention can be therapeutically administered as the neat chemical, but it is preferable to administer compounds of structural formula (II) as a pharmaceutical composition or formulation. Accordingly, the present invention further provides for pharmaceutical formula- tions comprising a compound of structural formula (II), together with one or more pharmaceutically acceptable carriers and, optionally, other therapeutic and/or prophylactic ingredients.
- the carriers are "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- a selective PDE4 inhibitor of the present invention is useful alone or in combination with a second antiinflammatory therapeutic agent, for example, a therapeutic agent targeting
- TNF ⁇ such as ENBREL ® or REMICADE ®
- ENBREL ® ENBREL ®
- REMICADE ® REMICADE ®
- therapeutic utility of IL-1 antagonism has also been shown in animal models for rheumatoid arthritis.
- IL-1 antagonism in combination with PDE4 inhibition, which attenuates TNF ⁇ , would be efficacious.
- the present PDE4 inhibitors are useful in the treatment of a variety of allergic, autoimmune, and inflammatory diseases.
- treatment includes preventing, lowering, stopping, or reversing the progression of severity of the condition or symptoms being treated.
- treatment includes both medical therapeutic and/or prophylactic administration, as appropriate .
- ⁇ inflammation is a local - ized, protective response elicited by injury or destruction of tissues, which serves to destroy, dilute or wall off (i.e.; sequester) both the injurious agent and the injured tissue.
- inflammatory disease means any dis- ease in which an excessive or unregulated inflammatory response leads to excessive inflammatory symptoms, host tissue damage, or loss of tissue function.
- autoimmune disease means any group of disorders in which tissue injury is associated with humoral or cell-mediated responses to the body's own constituents.
- allergic disease means any symptoms, tissue damage, or loss of tissue function resulting from allergy.
- arth- ritic disease means any of a large family of diseases that are characterized by inflammatory lesions of the joints attributable to a variety of etiologies.
- skintitis means any of a large family of diseases of the skin that are characterized by inflammation of the skin attributable to a variety of etiologies.
- transplant rejection means any immune reaction directed against grafted tissue (including organ and cell (e.g., bone marrow) ) , characterized by a loss of function of the grafted and surrounding tissues-, pain, swelling, leukocytosis and thrombocytopenia .
- the present invention also provides a method of modulating cAMP levels in a mammal, as well as a method of treating diseases characterized by elevated cytokine levels.
- cytokine means any secreted polypeptide that affects the functions of other cells, and that modulates interactions between cells in the immune or inflammatory response.
- Cytokines include, but are not limited to monokines, lymphokines, and chemokines regardless of which cells produce them.
- a monokine is generally referred to as being produced and secreted by a monocyte, however, many other cells produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epidermal keratinocytes, and B-lymphocytes .
- Lymphokines are generally referred to as being produced by lymphocyte cells.
- cytokines include, but are not limited to, interleukin-1 (IL-1) , inter- leukin-6 (IL-6), Tumor Necrosis Factor alpha (TNF ⁇ ),' and Tumor Necrosis Factor beta (TNF3) .
- IL-1 interleukin-1
- IL-6 inter- leukin-6
- TNF ⁇ Tumor Necrosis Factor alpha
- TNF3 Tumor Necrosis Factor beta
- the present invention further provides a method of reducing TNF levels in a mammal, which comprises administering an effective amount of a compound of structural formula (II) to the mammal.
- reducing TNF levels means either: a) decreasing excessive in vivo TNF levels in a mammal to normal levels -or below normal levels by inhibition of the in vivo release of TNF by all cells,, including but not limited to monocytes or macrophages; or b) inducing a down-regulation, at the translational or transcription level, of excessive in vivo TNF levels in a mammal to normal levels or below normal levels; or c) inducing a down-regulation, by inhi- bition of the direct synthesis of TNF as a postrans- lational event.
- inflammatory cell acti- vation means the induction by a stimulus (including, but not limited to, cytokines, antigens or auto-antibodies) of a proliferative cellular response, the production of soluble mediators (including but not limited to cytokines, oxygen radicals, enzymes, prostanoids, or vasoactive amines) , or cell surface expression of new or increased numbers of mediators (including, but not limited to, major histocompatability antigens or cell adhesion molecules) in inflammatory cells (in- eluding but not limited to monocytes, macrophages, T lymphocytes, B lymphocytes, granulocytes , poly- morphonuclear leukocytes, mast cells, basophils, eosinophils, dendritic cells, and endothelial cells) .
- a stimulus including, but not limited to, cytokines, antigens or auto-antibodies
- soluble mediators including but not limited to cytok
- the compounds of the present invention also are useful in causing airway smooth muscle relaxation, bronchodilation, and- prevention of bronchoconstriction .
- the compounds of the present ..invention therefore, are useful in treating such diseases as arthritic diseases (such as rheumatoid arthritis) , osteoarthritis, gouty arthritis, spondylitis, thyroid-associated ophthalmopathy, Behcet disease, sepsis, septic shock, endotoxic shock, gram negative sepsis, gram positive sepsis, toxic shock syndrome, asthma, chronic bronchitis, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis,, eosinophilic granulpma, adult (acute) respiratory distress syndrome (ARDS) , chronic pulmonary inflam- • matory disease (such as chronic obstructive pulmonary disease), silicosis, • pulmonary sarcoidosis, reperfusion injury of the myo
- GvH host
- allo- graft rejection chronic glomerulonephritis
- chronic glomerulonephritis inflammatory bowel diseases, such as Crohn ' s disease and ulcerative colitis
- proliferative lymphocytic diseases such as leukemias (e.g. chronic lympho- cytic leukemia; CLL) (see Mentz et al . , Blood 88 , pp. 2172-2182 (1996) )
- inflammatory dermatoses such as atopic dermatitis, psoriasis, or urticaria.
- diseases or related conditions include cardiomyopathies, such as congestive heart failure, pyrexia, cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS) , ARC (AIDS-related complex) , cerebral a- laria, osteoporosis and bone resorption diseases, and fever and myalgias due to infection.
- cardiomyopathies such as congestive heart failure, pyrexia, cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS) , ARC (AIDS-related complex) , cerebral a- laria, osteoporosis and bone resorption diseases, and fever and myalgias due to infection.
- AIDS acquired immune deficiency syndrome
- ARC AIDS-related complex
- cerebral a- laria such as depression and multi-infarct dementia
- Compounds of the present invention also have utility outside of that typically known as therapeutic.
- the present compounds can function as organ transplant preservatives (see Pinsky et al . , J. Clin . Invest . , 92, pp. 2994-3002 (1993) ) as well.
- PDE4-selective inhibitors show efficacy in a variety of animal models of depression such as the "behavioral despair” or Porsolt tests (Bur. J. Pharmacol . , 4-7, p. 379 (1978); Eur. J. Pharmacol . , 57, p. 431 (1979); Antidepressants : neurochemical , behavioral and clinical prospectives , Enna, Malick, and Richelson, eds . , Raven Press, p. 121 (1981)), and the "tail suspension test” ⁇ Psychopharmacology, 85, p. 367 (1985)).
- a selective PDE4 inhibitor can be used alone or in conjunction with a second therapeutic agent in a treatment for the four major classes of antide- pressants: electroconvulsive procedures, monoamine oxidase inhibitors, and selective reuptake inhibitors of serotonin or norepinephrine .
- Selective PDE4 inhibitors also can be useful in applications that modulate bronchodilatory activity via direct action on bronchial smooth muscle cells for the treatment of asthma .
- Compounds and pharmaceutical compositions suitable for use in the present invention include those wherein the active ingredient is administered to a mammal in an effective amount to achieve its intended purpose. More specifically, a "therapeutically effective amount” means an amount effective to prevent development of, or to alleviate the existing symptoms of, the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- the term "mammal” as used herein includes males and females, and encompasses humans, domestic animals (e.g., cats, dogs), livestock (e.g., cattle, horses, swine.), and wildlife (e.g., primates, large cats, zoo specimens).
- a “therapeutically effective dose” refers to that amount of the compound that results in achieving the desired effect .
- Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cul- tures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population) .
- the dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD 50 and ⁇ D 50 .
- Compounds which exhibit high therapeutic indices are preferred.
- the data obtained from such data can be used in formulating a dosage range for use m humans.
- the dosage of such compounds prefer- ably lies within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized. The exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the patient's condition. Dosage amount and interval can be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the therapeutic effects.
- reference herein to treatment extends to pro- phylaxis, as well as to treatment of established diseases or symptoms.
- the amount of a compound of the invention required for us.e in treatment varies with the nature of the condition being treated, and with the age and the condition of the patient, and is ultimately determined by the attendant physician or veterinarian.
- doses employed for adult human treatment typically are in the range of 0.001 mg/kg to about 100 mg/kg per day.
- the desired dose can be conveniently administered in a single dose, or as multiple doses administered at appropriate intervals, for example as two, three, four or more subdoses per day.
- the physician determines the actual dosing regimen which is most suit- able for an individual patient, and the dosage varies with the age, weight, and response of the particular patient .
- the above dosages are exemplary of the average case, but there can be individual instances in which higher or lower dosages are mer- ited, and such are within the scope of the present invention.
- Formulations of the present invention can be administered in a standard manner for the treatment of the indicated diseases, such as orally, parenterally, transmucosally (e.g., sublingually or via buccal administration) , topically, trans- der ally, rectally, via inhalation (e.g., nasal or deep lung inhalation) .
- Parenteral administration includes, but is not limited to intravenous, intra- arterial, intraperitoneal , subcutaneous, intramuscular, intrathecal, and intraarticular . Parenteral administration also can be accomplished using a high pressure technique, like POWDERJECTTM .
- the composition can be in the form of tablets or lozenges formulated in conventional manner.
- tablets and capsules for oral administration can contain conven- tional excipients such as binding agents (for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone) , fillers (for example, lactose, sugar, microcrystalline, cellulose, maize-starch, calcium phosphate or sorbi- tol) , lubricants (for example, magnesium, stearate, stearic acid, talc, polyethylene glycol or silica) , disintegrants (for example, potato starch or sodium starch glycollate) , or wetting agents (for example, sodium lauryl sulfate) .
- the tablets can be coated according to methods well known in the art.
- the compounds of the present invention can be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, for exam- pie.
- oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, for exam- pie.
- formulations containing these compounds can be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations can contain conventional additives, such as suspending agents, such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, hydroxy- propylmethylcellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats; emulsifying agents, such as lecithin, sorbitan mono- oleate, or acacia; nonaqueous vehicles (which can include edible oils) , such as almond oil, fractionated coconut oil, oily esters, propylene glycol, and ethyl alcohol,- and preservatives, such as methyl or propyl p-hydroxybenzoate and sorbic acid.
- suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, hydroxy- propylmethylcellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats
- emulsifying agents such as
- compositions for inhalation typically can be provided in the form of a solution, suspension, or emulsion that can be administered as a dry powder or in the form of an aerosol using a conventional propellant, such as dichlorodifluoromethane or trichlorofluoromethane ' .
- Typical topical and transdermal formulations comprise conventional aqueous or nonaqueous vehicles, such as eye drops, creams, ointments, lotions, and pastes, or are in the form of a medicated plaster, patch, or membrane.
- compositions of the present invention can be formulated for parenteral administration by injection or continuous infusion.
- Formulations for injection can be in the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulation agents, such as suspending, stabilizing, and/or dispersing agents.
- the active ingredient can be in powder form for constitution with a suitable vehicle (e.g., sterile, pyrogen-free water) before use.
- a composition in accordance with the present invention also can be formulated as a depot preparation.
- Such long acting formulations can be administered by implantation (for example, subcuta- neously or intramuscularly) or by intramuscular injection.
- the compounds of the invention can be formulated with suitable polymeric or 5 hydrophobic materials (e.g., an emulsion in an acceptable oil), ion exchange resins, or as sparingly soluble derivatives (e.g., a sparingly soluble salt) .
- the invention provides in a further aspect a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the formula (II) , together with a pharmaceutically acceptable diluent or carrier
- (II) can be prepared according to the following synthetic schemes. In each scheme described below, it is understood in the art that protecting groups can be employed where necessary in accordance with general principles of synthetic chemistry. These protecting groups are removed in the final steps of the synthesis under basic, acidic, or hydrogenolytic conditions which are readily apparent to those skilled in the art. By employing appropriate manipulation and protection of- any chemical functionalities, synthesis of compounds of structural formula (II) not specifically set forth herein can be accomplished by methods analogous to the schemes set forth below.
- the resulting solution was allowed to continue stirring at 0°C for 0.5 hour as the bubbling subsided, and then was allowed to warm to room temperature and stirred overnight (17 , hours) .
- the reaction was diluted with ethyl acetate (500 mL) and was carefully quenched with water (250 mL) . After vigorously stirring this mixture for 1 hour, the layers were separated, and the organic layer was washed with additional water (400 mL) and brine (400 mL) , then dried over MgS0 4 , filtered and concentrated in vacuo to provide an acid chloride as a brown solid (57.5 g; 98%).
- reaction mixture was allowed to slowly warm to 0°C over 40 minutes, during which time the reaction became a thick slurry. After stirring at 0°C for 2.5 hours, the reaction was quenched with saturated, aqueous ammonium chloride
- the following abbrevia- tions are used: NaOH (sodium hydroxide), CH 2 C1 2 (dichloromethane) , Na 2 S0 4 (sodium sulfate) , EtOAc (ethyl acetate) , Ph (phenyl) , MeOH ( ethanol) , K 2 C0 3 (potassium carbonate) , ⁇ mol (micromole) , atm (atmosphere) , MgS0 4 (magnesium sulfate) , LiOH (lithium hydroxide) , N (normal) , mmol (millimole) , mL (milli- liter) , and H 3 P0 4 (phosphoric acid) .
- reaction was diluted with 1:1 hexanes :EtOAc (30 mL) and washed successively with water (20 mL) and brine (20 mL) , then dried (MgS0 4 ) , filtered, and concentrated in vacuo to provide the sulfonamide.
- the compounds of structural formula (II) were tested for an ability to inhibit PDE .
- the ability of a compound to inhibit PDE4 activity is related to the IC 50 value for the compound, i.e., the concentration of inhibitor required for 50% inhibition of enzyme activity.
- the IC- 0 value for compounds of structural formula (II) were determined using recombinant human PDE4.
- the compounds of the present invention typically exhibit an IC 50 value against recombinant human PDE4 of less than about 100 ⁇ M, and preferably less than about 50 ⁇ M, and more preferably less than about 25 ⁇ .
- the compounds of the present invention typically exhibit an IC 50 value against recombinant human PDE4 of less than about 5 ⁇ M, and often less than about 1 ⁇ M .
- a present PDE4 inhibitor has an IC 50 of about 1 nM to about 25 ⁇ M .
- IC 50 values for the compounds were determined Erom concentration-response curves typically using concentrations ranging from 0.1 pM to 500 ⁇ M . Tests against other PDE enzymes using stan- dard methodology, as described in Loughney et al . ,
- the compounds of structural formula (II) also were tested for an ability to reduce TNF ⁇ secretion in human peripheral blood lymphocytes.
- the ability to reduce TNF ⁇ secretion is related to the EC 50 values (i.e., the effective concentration of the compound capable of inhibiting 50% of the total TNF ⁇ ) .
- the compounds of the present invention typically exhibit an EC 50 value of less than about 50 ⁇ M , and preferably less than about 25 ⁇ M , and more preferably less than about 15 ⁇ M .
- the compounds of the present invention preferably exhibit a PBL/TNF ⁇ EC 50 value of less than about 5 ⁇ M , and often less than about 0.10 ⁇ M .
- a present PDE4 inhibitor has an EC 50 value of about 10 nM to about 20 ⁇ M .
- the production of recombinant human PDEs and the IC 50 and EC 50 determinations can be accomplished by well-known methods in the art. Exemplary methods are described as follows: EXPRESSION OF HUMAN PDEs
- Baculovirus transfer plasmids were constructed using either pBlueBacIII (Invitrogen) or pFastBac (BRL-Gibco) . The structure of all plasmids was verified by sequencing across the vector junctions and by fully sequencing all regions generated by PCR.
- -Plasmid pBB-PDElA3/6 contained the complete open reading frame of PDE1A3 (Loughney et al . , J. Biol . Chem . , 271 , pp. 796-806 (1996)) in pBlue- BacIII .
- Plasmid Hcam3aBB contained the. complete open reading frame of PDE1C3 (Loughney et al .
- Plasmid pBB-PDE3A contained the complete open reading frame of PDE3A (Meacci et al . , Proc . Natl . Acad . Sci . , USA, 89, pp. 3721-3725 (1992)) in pBlueBacIII.
- Recombinant virus stocks were produced using either the MaxBac system (Invitrogen) or the FastBac system (Gibco-BRL) according to the manufacturer's protocols. In both cases, expression of recombinant human PDEs in the resultant viruses was driven off the viral polyhedron promoter.
- virus was plaque purified twice in order to insure that no wild type (occ+) virus contaminated the preparation.
- Protein expres- sion was carried out as follows. Sf9 cells were grown at 27°C in Grace's Insect culture medium (Gibco-BRL) supplemented with 10% fetal bovine serum, 0.33% TC yeastolate, 0.33% lactalbumin hydro- lysate, 4.2 mM NaHC0 3 , 10 ⁇ g/mL gentamycin, 100 units/mL penicillin, and 100 g/mL streptomycin. Exponentially growing cells were infected at a multiplicity of approximately 2 to 3 virus particles per cell and incubated for 48 hours. Cells were collected by centrifugation, washed with nonsup- plemented Grace's medium, and quick- frozen for storage.
- yeast ADH2 promoter and terminator sequences and the Saccharomyces cerevisiae host was the protease-defi- cient strain BJ2-54 deposited on August 31, 1998 with the American Type Culture Collection, Manassas, Virginia, under accession number ATCC 74465. Transformed host cells were grown in 2X SC-leu medium, pH 6.2, with trace metals, and vitamins. After 24 hours, YEP medium-containing glycerol was added to a final concentration of 2X YET/3% glycerol. Approximately 24 hr later, cells were harvested, washed, and stored at -70°C. HUMAN PHOSPHODIESTERASE PREPARATIONS
- Phosphodiesterase activity of the preparations was determined as follows. PDE assays utilizing a charcoal separation technique were performed essentially a-s described in Loughney et al . (1996) . In this assay, PDE activity converts [32P] cAMF or [32P]cGMP to the corresponding [32P]5'-AMP or
- [32P]5'-GMP in proportion to the amount of PDE activity present.
- the [32P] 5 ' -AMP or [32P] 5 ' -GMP then was quantitatively converted to free [32P] phosphate and unlabeled adenosine or guanosine by the action of snake venom 5 ' -nucleotidase .
- the amount of [32P] phosphate liberated is proportional to enzyme activity.
- the assay was performed- at 30°C in a 100 ⁇ h reaction mixture containing (final concentrations) 40 mM Tris HCl (pH 8.0), .1 M ZnS0 4 , 5 M MgCl 2 , and 0.1 mg/mL bovine serum albumin (BSA) .
- BSA bovine serum albumin
- incubation mixtures further incorporated the use of 0.1 mM CaCl 2 and 10 ⁇ g/ ⁇ h calmodulin.
- PDE enzyme was present in quantities that yield ⁇ 30% total hydrolysis of substrate (linear assay conditions) .
- the assay was initiated by addition of substrate (1 mM [32P] cAMP or cGMP) , and the mixture was incubated for 12 minutes. Seventy- five (75) ⁇ g of Crotalus atrox venom then was added, and the incubation was continued for 3 minutes (15 minutes total) .
- Yeast cells 50- g of yeast strain YI26 harboring HDUN1.46 were thawed at room temperature by mixing with 50 mL of Lysis Buffer (50 mM MOPS pH 7.5, 10 ⁇ M ZnS0 4 , 2 mM MgCl 2 , 14.2 mM 2-mercapto- ethanol, 5 ⁇ g/mL each of p ' epstatin, leupeptin, aprotinin, 20 ⁇ g/rriL each -of calpain inhibitors I and
- Lysis Buffer 50 mM MOPS pH 7.5, 10 ⁇ M ZnS0 4 , 2 mM MgCl 2 , 14.2 mM 2-mercapto- ethanol, 5 ⁇ g/mL each of p ' epstatin, leupeptin, aprotinin, 20 ⁇ g/rriL each -of calpain inhibitors I and
- PDE4A was precipitated from the high-speed supernatant by the addition of solid ammonium sulfate (0.26 g/mL supernatant) while stirring in an ice bath and maintaining the. pH between 7.0 and 7.5.
- the precipitated proteins containing PDE4A were collected via centrifugation in a Beckman JA-10 rotor at 9,000 rpm for 22 minutes.
- the precipitate was resuspended in 50 mL of Buffer G (50 mM MOPS pH
- the resuspended sample (50 to 100 mL) was- loaded onto a 5 X 100 cm column of Pharmacia ® SEPHACRYL S-300 equilibrated in Buffer G. Enzyme activity was eluted at a flow rate of 2 ' mL/min and pooled for later fractionation.
- the PDE4A isolated from gel filtration chromatography was applied to a 1.6 X 20 cm column of Sigma Cibacron Blue Agarose-type 300-- (10 mL) equilibrated in Buffer A (50 mM MOPS pH 7.5, 10 ⁇ M ZnS0 4 , 5 mM MgCl 2 , 14.2 mM- 2 -mercaptoethanol , and 100 mM benzamidine HCl) .
- Buffer A 50 mM MOPS pH 7.5, 10 ⁇ M ZnS0 4 , 5 mM MgCl 2 , 14.2 mM- 2 -mercaptoethanol , and 100 mM benzamidine HCl
- Buffer A 20 to 30 mL of Buffer A containing 20 mM 5 '-AMP, 50 to 100 mL of Buffer A containing 1.5 M NaCl , and 10 to 20 mL of Buffer C (50 mM Tris HCl pH 8, 10 ⁇ M ZnS0 4 , 14.2 mM 2 -mercaptoethanol , and 2 mM benzamidine HCl) .
- Buffer C 50 mM Tris HCl pH 8, 10 ⁇ M ZnS0 4 , 14.2 mM 2 -mercaptoethanol , and 2 mM benzamidine HCl.
- the enzyme was eluted with 20 to 30 mL of Buffer C containing 20 mM cAMP.
- the PDE activity peak was pooled, and precipitated with ammonium sulfate (0.33 g ' /mL enzyme pool) to remove excess cyclic nucleotide.
- the pre- cipitated proteins were resuspended in Buffer X (25 mM MOPS pH 7.5, 5 ⁇ M ZnS0 4 , 50 mM NaCl, 1 mM DTT, and 1 mM benzamidine HCl) , and desalted via gel
- the resultant preparations were about >80% pure by SDS-PAGE. These preparations had specific activities of about 10 to 40 ⁇ mol cAMP hydrolyzed per minute per milligram protein.
- Yeast cells 150 g of yeast strain YI23 harboring HDUN2.32 were thawed by mixing with 100 mL glass beads (0.5 mM, acid washed) and 150 mL Lysis Buffer (50 mM MOPS pH 7.2 / 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 2 mM benzamidine HCl, 5 /ig/mL each of pepstatin, leupeptin, aprotinin, calpain inhibitors I and II) at room temperature. The mixture was
- the supernatant was recovered and PDE4B was precipitated by the addition of solid ammonium sulfate (0.26 g/mL supernatant) while stirring in an ice bath and maintaining the pH between 7.0 and 7.5. This mixture was then centrifuged for 22 minutes in a Beckman J2 centrifuge using a JA-10 rotor at 9,000 rpm (12,000 X g) ..
- the supernatant was discarded and the pellet was dissolved in 200 mL of Buffer A (50 mM MOPS pH 7.5 , 5 mM MgCl 2 , 1 mM DTT, 1 mM benzamidine HCl, and 5 ig/mL each of leupeptin, pepstatin, and aprotinin) .
- Buffer A 50 mM MOPS pH 7.5 , 5 mM MgCl 2 , 1 mM DTT, 1 mM benzamidine HCl, and 5 ig/mL each of leupeptin, pepstatin, and aprotinin
- the resuspended sample- was loaded onto a 1.6 X 200 cm column (25 mL) of Sigma Cibacron Blue Agarose-type 300 equilibrated in Buffer A.
- the sample was cycled through the column 4 to 6 times over the course of 12 hours.
- the column was washed in succession, with 125 to- 250 mL of Buffer A, 125 to 250 mL of Buffer A containing 1.5 M NaCl, and 25 to 50 mL of Buffer A.
- the enzyme was eluted with 50 to 75 mL of Buffer E (50 mM Tris HCl pH 8, 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 2 mM benzamidine HCl, and 20 mM cAMP) and 50 to 75 mL of Buffer E containing 1 M NaCl.
- Buffer E 50 mM Tris HCl pH 8, 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 2 mM benzamidine HCl, and 20 mM cAMP
- the PDE activity peak was pooled, and precip- itated with ammonium sulfate (0.4 g/mL -enzyme pool) to remove excess cyclic n ⁇ cleotide.
- the precipitated proteins were resuspended in Buffer X (25 mM MOPS pH 7.5, 5 ⁇ M ZnS0 4 , 50 mM NaCl, 1 mM DTT, and 1 mM benzamidine HCl) and desalted- via gel filtration
- Yeast cells 150 g of 'yeast strain YI30 harboring HDUN3.48 were thawed by mixing with 100 mL glass beads (0.5 mM, acid washed) and 150 mL Lysis Buffer (50 mM MOPS pH 7.2, 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 2 mM benzamidine HCl, 5- /ig/mL each of pepstatin,- leupeptin, aprotinin, calpain inhibitors I and II) at room temperature. The mixture was
- the super- natant was discarded and the pellet was dissolved in 200 mL of Buffer A (50 mM MOPS pH 7.5 , 5 mM MgCl 2 , 1 mM DTT, 2 mM benzamidine HCl, and 5 /ig/mL each of leupeptin, pepstatin, and aprotinin) .
- Buffer A 50 mM MOPS pH 7.5 , 5 mM MgCl 2 , 1 mM DTT, 2 mM benzamidine HCl, and 5 /ig/mL each of leupeptin, pepstatin, and aprotinin
- the resuspended sample was loaded onto a 1.6 X 20 cm column (25 mL) of Sigma Cibacron Blue Agarose-type 300 equilibrated in Buffer A. The sample was cycled through the column 4 to 6 times over the course of 12 hours . The column was washed in succession with 125 to 250 mL of Buffer A, 125 to 250 mL of Buffer A containing 1.5 M NaCl, and then 5- 25 to 50 mL of Buffer A.
- the enzyme was eluted with 50 to 75 mL of Buffer E (50 mM Tris HCl pH 8 , 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 2 mM benzamidine HCl, and 20 mM cAMP) a.nd 50 to 75 mL of Buffer E containing 1 M NaCl.
- Buffer E 50 mM Tris HCl pH 8 , 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 2 mM benzamidine HCl, and 20 mM cAMP
- the resultant preparations were about >80% pure by SDS-PAGE. These preparations had specific activities of about 10 to 20 /imol cAMP hydrolyzed per minute per milligram protein.
- Yeast cells 100 g of yeast strain YI29 harboring HDUN4.11 were thawed by mixing with 150 mL glass beads (0.5 mM, acid washed) and 150 mL 30 Lysis Buffer (50 mM MOPS pH 7.2, 10 ⁇ M ZnS0 4 , 2 mM MgCl 2 , 14.2 mM 2 -mercaptoethanol , 2 mM benzamidine HCl, 5 ⁇ g/mL each of pepstatin, leupeptin, aprotinin, calpain inhibitors I and II) at room tempera- ture . The mixture was cooled to 4°C, transferred to
- the supernatant was recovered and centrifuged in a
- the resuspended sample was loaded onto a 1.6 X 20 cm column (10 mL) of Sigma Cibacron Blue Agarose-type 300 equilibrated in Buffer A. ' The column was washed in succession with 50 to 100 mL of Buffer A, 20 to 30 mL of Buffer A containing 20 mM 5 '-AMP, 50 to 100 mL of Buffer A containing 1.5 M NaCl, and then 10 to 20 L of Buffer C (50 mM Tris HCl pH 8, 10 ⁇ M ZnS0 4. , 14.2 mM 2 -mercaptoethanol, 2 mM benzamidine HCl) .
- Buffer C 50 mM Tris HCl pH 8, 10 ⁇ M ZnS0 4. , 14.2 mM 2 -mercaptoethanol, 2 mM benzamidine HCl
- the enzyme was eluted with 20 to 30 mL of Buffer C containing 20 mM cAMP .
- the PDE4D activity peak was pooled and precipitated with ammonium sulfate (0.4 g/mL enzyme pool) to remove excess cyclic nucleotide.
- the precipitated proteins were resuspended in Buffer X (25 mM MOPS pH 7.2, 5 ⁇ M ZnS0 4 , 50 mM NaCl, 1 mM DTT, and 1 mM benzamidine HCl) and desalted via gel fil-
- the resultant preparations were about >80 ⁇ pure by SDS-PAGE. These preparations had specific activities of about 20 to 50 ⁇ mol cAMP hydrolyzed per minute per milligram protein.
- PBL peripheral blood lymphocytes
- cAMP-elevating agents such as prostaglandin E21, forskolin, 8-bromo-cAMP, or dibutryl-cAMP
- LPS lipopolysaccharide
- PDE4 inhibitors such as rolipram
- TNF ⁇ secretion from human PBL was used as a standard for the ability of a compound to elevate intracellular cAMP concentrations and/or to inhibit PDE4 activity within the cell.
- Heparinized blood (approximately 30 mL) drawn from human volunteers was mixed 1:1 with
- ® mixture was mixed 1..-1 with HISTOPAQUE and centrifuged at 1,50.0 rpm at room temperature without braking in the swinging bucket of a Beckman model TJ6 centrifuge. Erythrocytes were centrifuged to the bottom of the tubes, and serum remained at the surface of the tubes .
- a layer containing lymphocytes was mixed 1..-1 with HISTOPAQUE and centrifuged at 1,50.0 rpm at room temperature without braking in the swinging bucket of a Beckman model TJ6 centrifuge. Erythrocytes were centrifuged to the bottom of the tubes, and serum remained at the surface of the tubes . A layer containing lymphocytes
- ELISA ® sorbent assay
- the cell-based assay provided the following results for various pyrrolidine compounds of the present invention.
- the EC 50 values i.e., effective concentration of the compound capable of inhibiting 50% of the total TNF ⁇
- the table below illustrates the ability of compounds of formula (II) to inhibit PDE4 activity and TNF ⁇ release in vi tro .
- the IC 50 values were determined against human recombinant PDE4. .
- the present compounds are potent inhibitors of PDE4 , e.g., the compounds have an IC 50 vs. human recombinant PDE4 of about 700 pM to about 15 ⁇ M.
- Preferred compounds have an IC 50 of about 100 nM or less, and especially preferred compounds have an IC 50 of about 50 nM or less.
- preferred compounds have a PBL/TNF ⁇ EC 50 about 500 nM or less, and preferably about 200 nM or less. More preferred compounds have a PBL/TNF ⁇ of about 100 nM or less.
- the compound has a IC 50 vs. human recombinant PDE4 of about 100 ⁇ M Or less and a PBL/TNF ⁇ EC 50 of about 500 ⁇ M or less. More preferably, : the compound has an IC 50 of about 50 nM or less and a PBL/TNF ⁇ EC 50 of about 100 nM or less.
- test animals were female Balb/c mice, having an average weight of about 20 g.
- the PDE4 The PDE4
- ® inhibitors formulated in 30% Cremophor EL, were administered via intraperitoneal (i.p.) injections at doses of 0.1, 1.0, 10.0, and 100 mg/kg. Individual dose volumes (about 150 ⁇ L) were adjusted based on the body weights measured. One hour later, 5 mg/kg LPS in a final volume of 200 ⁇ L was injected via the tail vein to each animal . Ninety minutes following the LPS treatment, the animals were bled and serum samples were collected before being stored at -70°C until assayed.
- the serum samples were .diluted two-fold and TNF ⁇ levels were
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00984450A EP1244619A1 (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit camp-specific pde |
EA200200591A EA007589B1 (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit camp-specific pde |
CA002395173A CA2395173A1 (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit camp-specific pde |
MXPA02006206A MXPA02006206A (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit campspecific pde. |
HU0300169A HUP0300169A3 (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit camp-specific pde, pharmaceutical compositions containing them and their use |
BR0016687-1A BR0016687A (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines that inhibit ampc specific powder |
AU21065/01A AU778795B2 (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit cAMP-specific PDE |
JP2001549352A JP2003519122A (en) | 1999-12-23 | 2000-12-15 | Pyrrolidine inhibiting cAMP-specific PDE |
PL00355893A PL355893A1 (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit camp-specific pde |
IL15028700A IL150287A0 (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit camp-specific pde |
KR1020027008161A KR20020063601A (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit camp-specific pde |
NO20023009A NO20023009L (en) | 1999-12-23 | 2002-06-21 | Pyrrolidines that inhibit CAMP-specific PDE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17202399P | 1999-12-23 | 1999-12-23 | |
US60/172,023 | 1999-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001047879A1 true WO2001047879A1 (en) | 2001-07-05 |
Family
ID=22626053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/034116 WO2001047879A1 (en) | 1999-12-23 | 2000-12-15 | Pyrrolidines which inhibit camp-specific pde |
Country Status (16)
Country | Link |
---|---|
US (1) | US6376489B1 (en) |
EP (1) | EP1244619A1 (en) |
JP (1) | JP2003519122A (en) |
KR (1) | KR20020063601A (en) |
CN (1) | CN1246311C (en) |
AU (1) | AU778795B2 (en) |
BR (1) | BR0016687A (en) |
CA (1) | CA2395173A1 (en) |
EA (1) | EA007589B1 (en) |
HU (1) | HUP0300169A3 (en) |
IL (1) | IL150287A0 (en) |
MX (1) | MXPA02006206A (en) |
NO (1) | NO20023009L (en) |
PL (1) | PL355893A1 (en) |
WO (1) | WO2001047879A1 (en) |
ZA (1) | ZA200205015B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7691853B2 (en) | 2000-09-15 | 2010-04-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7872129B2 (en) | 2002-08-02 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of GSK-3 |
US7951820B2 (en) | 2000-09-15 | 2011-05-31 | Vertex Pharmaceuticals Incorporated | Triazole compounds useful as protein kinase inhibitors |
US8304414B2 (en) | 2000-12-21 | 2012-11-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP3150578A4 (en) * | 2014-05-29 | 2017-12-06 | Mitsubishi Tanabe Pharma Corporation | Novel pyrrolidine compound and application as melanocortin receptor agonist |
WO2019065954A1 (en) | 2017-09-29 | 2019-04-04 | 田辺三菱製薬株式会社 | Optically active pyrrolidine compound and method for producing same |
CN111333626A (en) * | 2018-12-18 | 2020-06-26 | 湖北生物医药产业技术研究院有限公司 | Phenyl pyrrolidine compounds and uses thereof |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6680336B2 (en) * | 1999-12-15 | 2004-01-20 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6794192B2 (en) * | 2000-06-29 | 2004-09-21 | Pfizer Inc. | Target |
US20050101000A1 (en) * | 2002-12-11 | 2005-05-12 | Isis Pharmaceuticals Inc. | Modulation of phosphodiesterase 4B expression |
US7138423B2 (en) * | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
JP2009506069A (en) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | Neurogenesis through modulation of muscarinic receptors |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
JP2010502722A (en) | 2006-09-08 | 2010-01-28 | ブレインセルス,インコーポレイティド | Combinations containing 4-acylaminopyridine derivatives |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
TWI617553B (en) * | 2013-03-13 | 2018-03-11 | 美國禮來大藥廠 | Azetidinyloxyphenylpyrrolidine compounds |
CN113563246A (en) * | 2020-04-29 | 2021-10-29 | 广东东阳光药业有限公司 | Substituted aza five-membered ring derivative and application thereof in medicine |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3935217A (en) * | 1973-02-28 | 1976-01-27 | Yoshitomi Pharmaceutical Industries, Ltd. | Substituted pyrrolidinemethanols |
WO1992019594A1 (en) * | 1991-05-02 | 1992-11-12 | Smithkline Beecham Corporation | Pyrrolidinones |
WO1995008534A1 (en) * | 1993-09-20 | 1995-03-30 | Glaxo Wellcome Inc. | 3-(3,4-dioxyphenyl)-pyrrolidines as type iv phosphodiesterase inhibitors for the treatment of inflammatory diseases |
EP0671389A1 (en) * | 1994-03-08 | 1995-09-13 | Mitsubishi Chemical Corporation | 3-Phenylpyrrolidine derivatives |
WO1997025312A1 (en) * | 1996-01-12 | 1997-07-17 | Schering Aktiengesellschaft | NEW ROLIPRAM DERIVATIVES AS cAMP-PDE IV INHIBITORS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ281170B6 (en) * | 1991-05-02 | 1996-07-17 | Daiichi Pharmaceutical Co., Ltd | The use of n-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide for preparing a pharmaceutical preparation |
GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
US5908858A (en) * | 1996-04-05 | 1999-06-01 | Sankyo Company, Limited | 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses |
-
2000
- 2000-12-07 US US09/731,591 patent/US6376489B1/en not_active Expired - Fee Related
- 2000-12-15 MX MXPA02006206A patent/MXPA02006206A/en active IP Right Grant
- 2000-12-15 KR KR1020027008161A patent/KR20020063601A/en not_active Application Discontinuation
- 2000-12-15 IL IL15028700A patent/IL150287A0/en unknown
- 2000-12-15 PL PL00355893A patent/PL355893A1/en not_active Application Discontinuation
- 2000-12-15 WO PCT/US2000/034116 patent/WO2001047879A1/en not_active Application Discontinuation
- 2000-12-15 CA CA002395173A patent/CA2395173A1/en not_active Abandoned
- 2000-12-15 EP EP00984450A patent/EP1244619A1/en not_active Withdrawn
- 2000-12-15 AU AU21065/01A patent/AU778795B2/en not_active Ceased
- 2000-12-15 HU HU0300169A patent/HUP0300169A3/en unknown
- 2000-12-15 EA EA200200591A patent/EA007589B1/en not_active IP Right Cessation
- 2000-12-15 CN CNB008191182A patent/CN1246311C/en not_active Expired - Fee Related
- 2000-12-15 JP JP2001549352A patent/JP2003519122A/en active Pending
- 2000-12-15 BR BR0016687-1A patent/BR0016687A/en not_active Application Discontinuation
-
2002
- 2002-06-21 ZA ZA200205015A patent/ZA200205015B/en unknown
- 2002-06-21 NO NO20023009A patent/NO20023009L/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3935217A (en) * | 1973-02-28 | 1976-01-27 | Yoshitomi Pharmaceutical Industries, Ltd. | Substituted pyrrolidinemethanols |
WO1992019594A1 (en) * | 1991-05-02 | 1992-11-12 | Smithkline Beecham Corporation | Pyrrolidinones |
WO1995008534A1 (en) * | 1993-09-20 | 1995-03-30 | Glaxo Wellcome Inc. | 3-(3,4-dioxyphenyl)-pyrrolidines as type iv phosphodiesterase inhibitors for the treatment of inflammatory diseases |
EP0671389A1 (en) * | 1994-03-08 | 1995-09-13 | Mitsubishi Chemical Corporation | 3-Phenylpyrrolidine derivatives |
WO1997025312A1 (en) * | 1996-01-12 | 1997-07-17 | Schering Aktiengesellschaft | NEW ROLIPRAM DERIVATIVES AS cAMP-PDE IV INHIBITORS |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7691853B2 (en) | 2000-09-15 | 2010-04-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7951820B2 (en) | 2000-09-15 | 2011-05-31 | Vertex Pharmaceuticals Incorporated | Triazole compounds useful as protein kinase inhibitors |
US8304414B2 (en) | 2000-12-21 | 2012-11-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US8697698B2 (en) | 2000-12-21 | 2014-04-15 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7872129B2 (en) | 2002-08-02 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of GSK-3 |
US9981960B2 (en) | 2014-05-29 | 2018-05-29 | Mitsubishi Tanabe Pharma Corporation | Pyrrolidine compound and application as melanocortin receptor agonist |
EP3150578A4 (en) * | 2014-05-29 | 2017-12-06 | Mitsubishi Tanabe Pharma Corporation | Novel pyrrolidine compound and application as melanocortin receptor agonist |
WO2019065954A1 (en) | 2017-09-29 | 2019-04-04 | 田辺三菱製薬株式会社 | Optically active pyrrolidine compound and method for producing same |
US11053217B2 (en) | 2017-09-29 | 2021-07-06 | Mitsubishi Tanabe Pharma Corporation | Optically active pyrrolidine compound and method for producing same |
EP4273141A1 (en) | 2017-09-29 | 2023-11-08 | Mitsubishi Tanabe Pharma Corporation | Optically active pyrrolidine compound and method for producing same |
US11845738B2 (en) | 2017-09-29 | 2023-12-19 | Mitsubishi Tanabe Pharma Corporation | Optically active pyrrolidine compound and method for producing same |
CN111333626A (en) * | 2018-12-18 | 2020-06-26 | 湖北生物医药产业技术研究院有限公司 | Phenyl pyrrolidine compounds and uses thereof |
CN111333626B (en) * | 2018-12-18 | 2022-10-18 | 武汉人福创新药物研发中心有限公司 | Phenyl pyrrolidine compounds and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
BR0016687A (en) | 2003-02-25 |
CA2395173A1 (en) | 2001-07-05 |
IL150287A0 (en) | 2002-12-01 |
KR20020063601A (en) | 2002-08-03 |
EP1244619A1 (en) | 2002-10-02 |
EA007589B1 (en) | 2006-12-29 |
HUP0300169A3 (en) | 2009-03-30 |
AU2106501A (en) | 2001-07-09 |
EA200200591A1 (en) | 2002-12-26 |
MXPA02006206A (en) | 2004-02-26 |
ZA200205015B (en) | 2004-04-08 |
AU778795B2 (en) | 2004-12-23 |
CN1434798A (en) | 2003-08-06 |
CN1246311C (en) | 2006-03-22 |
JP2003519122A (en) | 2003-06-17 |
HUP0300169A2 (en) | 2003-05-28 |
NO20023009D0 (en) | 2002-06-21 |
US6376489B1 (en) | 2002-04-23 |
PL355893A1 (en) | 2004-05-31 |
NO20023009L (en) | 2002-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6376489B1 (en) | Cyclic AMP-specific phosphodiesterase inhibitors | |
AU778593B2 (en) | 3-thiazol-4-yl-pyprolidine derivatives as AMP-specific phosphodiesterase inhibitors | |
US6458787B1 (en) | Cyclic AMP-specific phosphodiesterase inhibitors | |
US6348602B1 (en) | Cyclic AMP-specific phosphodiesterase inhibitors | |
WO2001047880A1 (en) | Cyclic amp-specific phosphodiesterase inhibitors | |
US6680336B2 (en) | Cyclic AMP-specific phosphodiesterase inhibitors | |
US6455562B1 (en) | Cyclic AMP-specific phosphodiesterase inhibitors | |
US6362213B1 (en) | Cyclic AMP-specific phosphodiesterase inhibitors | |
EP1244649B1 (en) | Cyclic amp-specific phosphodiesterase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 150287 Country of ref document: IL Ref document number: 21065/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2395173 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/05015 Country of ref document: ZA Ref document number: PA/a/2002/006206 Country of ref document: MX Ref document number: 200205015 Country of ref document: ZA Ref document number: IN/PCT/2002/948/CHE Country of ref document: IN Ref document number: 200200591 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027008161 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2001 549352 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000984450 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027008161 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008191182 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000984450 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 21065/01 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000984450 Country of ref document: EP |